Helene Aschmann, PhD | UCSF Center for TB

A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland.

Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V

Assessment of Patient-Preferred Language to Achieve Goal-Aligned Deprescribing in Older Adults.

Green AR, Aschmann H, Boyd CM, Schoenborn N

[Cancer Screening - Prerequesites for a Successful and Meaningful Screening Program].

Aschmann HE, Puhan MA

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.

Yebyo HG, Zappacosta S, Aschmann HE, Haile SR, Puhan MA

Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS.

Spanu A, Aschmann HE, Kesselring J, Puhan MA

Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit-Harm Assessments.

Aschmann HE, Boyd CM, Robbins CW, Chan WV, Mularski RA, Bennett WL, Sheehan OC, Wilson RF, Bayliss EA, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA

Outcome preferences of older people with multiple chronic conditions and hypertension: a cross-sectional survey using best-worst scaling.

Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Chan WV, Mularski RA, Wilson RF, Bennett WL, Sheehan OC, Yu T, Yebyo HG, Leff B, Tabano H, Armacost K, Glover C, Maslow K, Mintz S, Boyd CM

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit-harm balance modeling study.

Yebyo HG, Aschmann HE, Menges D, Boyd CM, Puhan MA

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment.

Addiction (Abingdon, England)

Aschmann HE, Boyd CM, Robbins CW, Mularski RA, Chan WV, Sheehan OC, Wilson RF, Bennett WL, Bayliss EA, Yu T, Leff B, Armacost K, Glover C, Maslow K, Mintz S, Puhan MA

Statins for Primary Prevention of Cardiovascular Disease.

Yebyo HG, Aschmann HE, Puhan MA

A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions.

Bennett WL, Aschmann HE, Puhan MA, Robbins CW, Bayliss EA, Wilson R, Mularski RA, Chan WV, Leff B, Sheehan O, Glover C, Maslow K, Armacost K, Mintz S, Boyd CM